日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Mechanisms Underlying Cedazuridine-Mediated Enhancement of Oral Decitabine Bioavailability.

Cedazuridine介导增强口服地西他滨生物利用度的机制。

Anabtawi Nadeen, Drabison Thomas, Ham Alexander F, Boeckman Mike, Stromatt Jack C, Orwick Shelley J, Buelow Daelynn R, Kaur Tejinder, Ahmed Eman A, Eisenmann Eric D, Govindarajan Rajgopal, Sparreboom Alex, Baker Sharyn D

Drug-Drug Interaction Liabilities with BTK Inhibitor TL-895

BTK抑制剂TL-895的药物相互作用风险

Stromatt, Jack C; Ahmed, Eman A; Drabison, Thomas; Nepal, Mahesh R; Chowdhury, Anika T; Orwick, Shelley J; Buelow, Daelynn R; Eisenmann, Eric D; Huang, Kevin M; Sparreboom, Alex; Baker, Sharyn D

Drug-drug interactions in targeted cancer therapies: a focus on tyrosine kinase inhibitors

靶向癌症治疗中的药物相互作用:以酪氨酸激酶抑制剂为例

Stromatt, Jack C; Chowdhury, Anika T; Huang, Kevin M; Hu, Shuiying; Sparreboom, Alex; Baker, Sharyn D; Eisenmann, Eric D

BMX kinase mediates gilteritinib resistance in FLT3-mutated AML through microenvironmental factors

BMX激酶通过微环境因素介导FLT3突变型急性髓系白血病(AML)的吉瑞替尼耐药性

Buelow, Daelynn R; Bhatnagar, Bhavana; Orwick, Shelley J; Jeon, Jae Yoon; Eisenmann, Eric D; Stromatt, Jack C; Pabla, Navjot Singh; Blachly, James S; Baker, Sharyn D; Blaser, Bradley W

TP-0903 Is Active in Preclinical Models of Acute Myeloid Leukemia with TP53 Mutation/Deletion

TP-0903 在 TP53 突变/缺失的急性髓系白血病临床前模型中有效

Eric D Eisenmann, Jack C Stromatt, Sydney Fobare, Kevin M Huang, Daelynn R Buelow, Shelley Orwick, Jae Yoon Jeon, Robert H Weber, Bill Larsen, Alice S Mims, Erin Hertlein, John C Byrd, Sharyn D Baker

Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia

一项随机 II 期研究,比较奥妥珠单抗联合苯达莫司汀与单用苯达莫司汀治疗复发性慢性淋巴细胞白血病患者的疗效。

Robak, Tadeusz; Hellmann, Andrzej; Kloczko, Janusz; Loscertales, Javier; Lech-Maranda, Ewa; Pagel, John M; Mato, Anthony; Byrd, John C; Awan, Farrukh T; Hebart, Holger; Garcia-Marco, Jose A; Hill, Brian T; Hallek, Michael; Eisenfeld, Amy J; Stromatt, Scott C; Jaeger, Ulrich

A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia

一项评估奥特妥珠单抗(一种抗CD37单特异性ADAPTIR治疗蛋白)在慢性淋巴细胞白血病中安全性和耐受性的I期研究

Byrd, John C; Pagel, John M; Awan, Farrukh T; Forero, Andres; Flinn, Ian W; Deauna-Limayo, Delva P; Spurgeon, Stephen E; Andritsos, Leslie A; Gopal, Ajay K; Leonard, John P; Eisenfeld, Amy J; Bannink, Jeannette E; Stromatt, Scott C; Furman, Richard R

Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients

一项针对复发性惰性淋巴瘤患者的 1b 期研究,评估抗 CD37 单特异性 ADAPTIR™ 治疗蛋白 otlertuzumab (TRU-016) 与利妥昔单抗和苯达莫司汀联合用药的疗效。

Gopal, Ajay K; Tarantolo, Stefano R; Bellam, Naresh; Green, Damian J; Griffin, Melissa; Feldman, Tatyana; Mato, Anthony R; Eisenfeld, Amy J; Stromatt, Scott C; Goy, Andre

Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals

四跨膜蛋白CD37直接介导存活和凋亡信号的转导。

Lapalombella, Rosa; Yeh, Yuh-Ying; Wang, Liwen; Ramanunni, Asha; Rafiq, Sarwish; Jha, Shruti; Staubli, Justin; Lucas, David M; Mani, Rajeswaran; Herman, Sarah E M; Johnson, Amy J; Lozanski, Arletta; Andritsos, Leslie; Jones, Jeffrey; Flynn, Joseph M; Lannutti, Brian; Thompson, Peter; Algate, Paul; Stromatt, Scott; Jarjoura, David; Mo, Xiaokui; Wang, Dasheng; Chen, Ching-Shih; Lozanski, Gerard; Heerema, Nyla A; Tridandapani, Susheela; Freitas, Michael A; Muthusamy, Natarajan; Byrd, John C

Police and prosecution systems: An evaluation of a police criminal case preparation program

警务和检控系统:对一项警务刑事案件准备计划的评估

Domash, M A; Schnelle, J F; Stromatt, E L; Carr, A F; Larson, L D; Kirchner, R E; Risley, T R